China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering

Investors receive warrants with a zero cash exercise option and a 30-day right to purchase up to $12 million of additional securities.

Rhea-AI Summary

China SXT Pharmaceuticals (SXTC) signed a definitive agreement with institutional investors for a registered direct offering expected to raise approximately $12 million.

The offering comprises 8,000,000 Class A ordinary shares, or pre-funded warrants in lieu thereof, at $1.50 per share, plus 8,000,000 warrants exercisable at $1.50 per share. The warrants are immediately exercisable, have a 1-year term and include a zero cash exercise option allowing holders to acquire up to 9 Class A shares per warrant. Investors also have a right to purchase up to $12 million of securities on the same terms during the 30-day period after closing. The company expects closing on or about October 9, 2026, subject to customary closing conditions. Gross proceeds exclude placement agent fees and other offering expenses.

1 point · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 4 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Registered direct offering expected to raise approximately $12 million in gross proceeds. 3.2× market cap

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.8,000,000 Class A shares, or pre-funded warrants in lieu thereof, at $1.50 per share introduce dilution.
• Minor point. Forward-looking: it has not happened yet and may not happen.8,000,000 warrants at $1.50 exercise price are immediately exercisable for 1 year; zero cash exercise permits up to 9 shares each.
• Minor point. Forward-looking: it has not happened yet and may not happen.Investors' additional purchase right permits up to $12 million of securities on identical terms within 30 days after closing.
• Minor point. Forward-looking: it has not happened yet and may not happen.Placement agent fees and other offering expenses will reduce the company's gross proceeds.

News Explained

China SXT Pharmaceuticals has signed an agreement, not yet closed, to sell 8 million shares or pre-funded warrants and issue 8 million warrants; if shares are issued or acquired on exercise, the added shares reduce existing holders’ percentage ownership.

Argus 15 min delay 121 alerts

-85.79% vs previous close $0.40 last price 859.6x rel. volume Open Argus

Details

Market move: SXTC -85.79% vs previous close. $12 million registered direct offering

+1.4% Peak Tracked

-14.2% Trough Tracked

$0.32 – $2.46 Day Range

$531,342 Market Cap

On Oct 8, the day this news came out, the latest delayed price for SXTC is 85.79% below the previous close. Argus tracked a peak move of +1.4% during the session. Argus tracked a trough of -14.2% from its starting point during tracking. Our momentum scanner has recorded 121 alerts for this stock so far that day. The latest delayed price is $0.40. Relative volume is exceptionally heavy at 859.6x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Shares offered: 8,000,000 Class A ordinary shares Purchase price: $1.50 per share Warrants issued: 8,000,000 warrants +5 more

Shares offered

8,000,000 Class A ordinary shares

Or pre-funded warrants in lieu thereof

Purchase price

$1.50 per share

Registered direct offering

Warrants issued

8,000,000 warrants

Issued to the same investors

Warrant exercise price

$1.50 per share

Immediately exercisable upon issuance

Warrant term

1 year

From the date of issuance

Zero-cash exercise

Up to 9 Class A shares per warrant

Zero cash exercise option

Expected gross proceeds

Approximately $12 million

Before placement agent fees and other offering expenses

Additional purchase right

Up to $12 million of securities

Same terms during the 30-day period after closing

Previous Offering Reports

2 past events · Latest: Jul 23

Same Type 2 events

1. Jul 23

   Registered offering

   24h Move

   -83.5%

   Prior direct deal paired shares with warrants at $2.00 per unit, with $9 million gross proceeds.

2. Jan 09

   Registered offering

   24h Move

   -87.9%

   Prior direct offering priced 66,666,666 shares at $0.15, with expected gross proceeds of $10 million.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

registered direct offering, pre-funded warrants, zero cash exercise option, shelf registration statement, +1 more

5 terms

registered direct offering financial

"at a purchase price of $1.50 per share in a registered direct offering"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

pre-funded warrants financial

"or pre-funded warrants in lieu thereof"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

zero cash exercise option financial

"a zero cash exercise option permitting the holder to acquire up to 9 Class A shares"

A zero cash exercise option lets a holder convert an option into shares without handing over money by surrendering a portion of the newly issued shares to cover the cost and any taxes, like getting an item by returning part of it instead of paying cash. For investors this matters because it changes how many new shares actually enter the market and whether a company needs cash to fulfill the grant, affecting ownership percentages and per-share metrics.

shelf registration statement regulatory

"made pursuant to a shelf registration statement on Form F-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"A final prospectus supplement and accompanying prospectus describing the terms"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TAIZHOU, China, Oct. 8, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8,000,000 Class A ordinary shares of the company, no par value per share (the "Shares") (or pre-funded warrants in lieu thereof), at a purchase price of $1.50 per share in a registered direct offering.

The Company also agreed to issue to the same investors 8,000,000 warrants (the "Warrants") with an exercise price of $1.50 per share. The Warrants will be immediately exercisable upon issuance and have a 1-year term from the date of issuance. Each warrant has a zero cash exercise option permitting the holder to acquire up to 9 Class A shares.

The aggregate gross proceeds to the Company of this offering are expected to be approximately $12 million, before deducting placement agent fees and other offering expenses payable by the Company. Investors will have an additional purchase right to acquire up to $12 million of securities on the same terms and conditions during the 30-day period after closing. The offering is expected to close on or about October 9, 2026, subject to the satisfaction of customary closing conditions.

Univest Securities, LLC is acting as the sole placement agent.

The registered direct offering is being made pursuant to a shelf registration statement on Form F-3 (File No. 333-291428) previously filed by the Company with the U.S. Securities and Exchange Commission ("SEC") and became effective on December 1, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Univest Securities, LLC at info@univest.us, or by calling +1 (212) 343-8888.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Copies of the prospectus supplement relating to the registered direct offering, together with the accompanying base prospectus will be filed by the Company and, upon filing, can be obtained at the SEC's website at www.sec.gov.

About China SXT Pharmaceuticals Inc.

Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit www.sxtchina.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the U.S. Securities and Exchange Commission.

China SXT Pharmaceuticals Inc.
Feng Zhou, Chief Executive Officer
Email: fzhou@sxtchina.com

View original content:https://www.prnewswire.com/news-releases/china-sxt-pharmaceuticals-inc-announces-12-million-registered-direct-offering-302902504.html

SOURCE China SXT Pharmaceuticals Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is China SXT Pharmaceuticals expected to raise in its registered direct offering?

China SXT Pharmaceuticals expects approximately $12 million in gross proceeds, before placement agent fees and other offering expenses. The agreement covers 8,000,000 Class A ordinary shares, or pre-funded warrants in lieu thereof, at $1.50 per share, together with 8,000,000 warrants.

When is China SXT Pharmaceuticals' registered direct offering expected to close?

China SXT Pharmaceuticals expects the offering to close on or about October 9, 2026, subject to satisfaction of customary closing conditions.